Terpene Biosynthesis in Cannabis
The biochemical machinery that produces cannabis terpenes and shapes strain aroma.
Cannabis terpene biosynthesis is well understood at the enzymatic level — we know which genes code for which enzymes and what products they make. What we don't know is how subtle differences in terpene ratios translate to subjective effects in humans. The leap from 'this flower has 0.8% myrcene' to 'this will couch-lock you' is marketing logic, not biochemistry.
What terpene biosynthesis is
Terpenes are a large family of hydrocarbons built from five-carbon isoprene units. In cannabis, as in all plants, every terpene ultimately derives from two universal C5 building blocks: isopentenyl diphosphate (IPP) and its isomer dimethylallyl diphosphate (DMAPP) [1][2]. These are condensed head-to-tail by prenyltransferases into longer prenyl diphosphates — geranyl diphosphate (GPP, C10) for monoterpenes, farnesyl diphosphate (FPP, C15) for sesquiterpenes, and geranylgeranyl diphosphate (GGPP, C20) for diterpenes [1]. Strong evidence
Those prenyl diphosphates are then handed off to terpene synthases (TPSs), the enzymes that catalyze the interesting chemistry: they ionize the substrate and guide it through carbocation rearrangements, cyclizations, and quenching steps to produce specific terpene skeletons [1][3]. Critically, a single TPS can often make several products from one substrate — sometimes a dominant product and several minor byproducts — which is part of why cannabis chemotypes show natural variation even when genetically similar [3][8]. Strong evidence
The two parallel pathways
Plants run two independent metabolic pathways to generate IPP and DMAPP, and cannabis employs both [2][4]:
MEP pathway (methylerythritol phosphate), located in plastids. It starts from pyruvate and glyceraldehyde-3-phosphate and primarily feeds monoterpenes (C10: myrcene, limonene, pinene, etc.) and the GPP precursor used for cannabinoid biosynthesis [2][4]. Strong evidence
MVA pathway (mevalonate), located in the cytosol. It starts from acetyl-CoA and primarily feeds sesquiterpenes (C15: β-caryophyllene, humulene, etc.) [2][4]. Strong evidence
While some IPP can cross the plastid membrane, in practice the monoterpene vs. sesquiterpene split tracks the MEP/MVA compartmentalization reasonably well [2][4]. A notable consequence: the prenyl side chain of cannabinoids (the geranyl group attached to olivetolic acid to form CBGA) also comes from MEP via GPP, which means monoterpene biosynthesis and cannabinoid biosynthesis compete for the same precursor pool [5]. This metabolic competition may partly explain why high-cannabinoid cultivars sometimes show lower terpene diversity or concentration [5]. Weak / limited
Where it happens: glandular trichomes
Terpene and cannabinoid biosynthesis is concentrated in glandular trichomes on female inflorescences and bracts, especially the capitate-stalked trichomes — the sticky resinous heads visible to the naked eye [5][6]. Transcriptomic studies have shown that trichome secretory cells express terpene synthase genes and cannabinoid pathway genes at far higher levels than leaf, stem, or root tissue [5][6]. Strong evidence
The secreted terpenes accumulate in extracellular storage cavities within the trichome head, alongside cannabinoids in their acidic (non-psychoactive) forms. Because terpenes are volatile, substantial loss occurs during drying, curing, and storage — particularly the lighter monoterpenes with lower boiling points — which is why fresh flower smells distinctly different from aged flower and why concentrate chemistry rarely matches the source flower one-to-one [7]. Strong evidence
Cloning and characterizing cannabis terpene synthases
Functional characterization of cannabis TPSs accelerated in the 2010s, particularly following the release of the genome sequence. Booth, Page, and Bohlmann (2017) cloned and biochemically characterized a set of cannabis monoterpene and sesquiterpene synthases, assigning specific products to specific enzymes — including (-)-limonene synthase, (-)-myrcene synthase, (E)-β-ocimene synthase, (-)-α-pinene synthase, and multiple sesquiterpene synthases including a bifunctional β-caryophyllene/α-humulene synthase [3]. Strong evidence
A follow-up comprehensive study (Booth et al., 2020) expanded the TPS catalog and directly linked differences in enzyme expression and repertoire to chemotype variation between cultivars [8]. Strong evidence
Key findings:
- Most cannabis TPSs are multi-product enzymes. A single 'myrcene synthase' typically produces myrcene as the major product but also minor amounts of limonene, pinene, or other monoterpenes depending on reaction conditions and substrate ratio [3][8]. Strong evidence
- Chemotype differences arise from both genetic and regulatory causes. Two cultivars with the same TPS genes but different expression levels or different substrate availability will produce different terpene profiles [8]. Strong evidence
- The 'indica vs. sativa' label has no predictive relationship to terpene profile at the chemistry level; this is marketing rather than botany. GC-MS chemotyping is far more informative [9]. Strong evidence
Effects research: what we know and don't
The biochemistry above is firmly established by peer-reviewed research. The leap from 'this cultivar contains 0.8% myrcene' to 'this cultivar will produce a couch-lock effect' is a different claim entirely, and the evidence gap is substantial.
Most published claims about terpene-specific effects in cannabis rest on one or more of the following:
- In vitro receptor binding assays, where purified terpenes are tested at concentrations often 100–1000× higher than achieved by smoking or vaping flower Weak / limited
- Rodent behavioral studies with isolated terpenes, which may not translate directly to human perception or physiology Weak / limited
- Extrapolation from aromatherapy literature, which uses different exposure routes and concentrations Anecdote
Controlled human trials testing specific terpene profiles in inhaled cannabis while holding cannabinoid content constant are rare. The ones that exist have generally not found large, reliable subjective or physiological effects attributable to terpenes independent of THC and CBD dose Weak / limited. The popular rule that 'myrcene above 0.5% produces couch-lock,' in particular, has no published primary source and should be treated as folklore. No data
This does not mean terpenes are pharmacologically inert. β-caryophyllene, for instance, binds the CB2 cannabinoid receptor with measurable affinity and has documented anti-inflammatory effects in animal models Weak / limited. But honesty requires acknowledging that the biochemistry is ahead of the clinical evidence.
Terpene chemotypes in cultivars
Large-scale chemical analysis of commercial cannabis flower reveals that hundreds of distinct strain names cluster into a small number of recurring terpene chemotypes, regardless of reported variety name [9]. This reflects the fact that TPS expression is sensitive to genetics, light exposure, nutrient availability, and harvest timing; the same cultivar from different growers can land in different clusters [8][9]. Strong evidence
The most common patterns in North American flower are:
- Myrcene-dominant (often with secondary pinene or limonene) — the most frequent profile in retail samples
- Limonene-dominant (often with caryophyllene)
- Terpinolene-dominant (associated with 'Jack Herer' and Haze-type genetics)
- β-Caryophyllene-dominant sesquiterpene profiles, sometimes with humulene
The reliability of strain names as predictors of chemistry is poor — the same name from different seedbanks, regions, or harvest years often shows divergent profiles — which is consistent with what we know about polygenic control of TPS expression and environmental sensitivity [9]. Strong evidence
Related biochemistry and articles
For detailed biochemistry of specific terpenes produced by this pathway, see articles on individual monoterpenes (e.g., Pinene, Cis-Ocimene) and sesquiterpenes (overview, Beta-Caryophyllene).
For the parallel cannabinoid pathway that shares GPP precursor pools with monoterpene biosynthesis, see Decarboxylation Chemistry.
For how terpenes are lost or modified during post-harvest handling, see Terpene Degradation During Drying.
For the evidence (or lack thereof) that terpene profiles predict effects, see Terpene Profiles Reliably Predict Effects and Why Terpenes Matter (Or Don't).
Sources
- Peer-reviewed Chen F, Tholl D, Bohlmann J, Pichersky E. (2011). The family of terpene synthases in plants: a mid-size family of genes for specialized metabolism that is highly diversified throughout the kingdom. The Plant Journal, 66(1), 212–229.
- Peer-reviewed Vranová E, Coman D, Gruissem W. (2013). Network analysis of the MVA and MEP pathways for isoprenoid synthesis. Annual Review of Plant Biology, 64, 665–700.
- Peer-reviewed Booth JK, Page JE, Bohlmann J. (2017). Terpene synthases from Cannabis sativa. PLOS ONE, 12(3), e0173911.
- Peer-reviewed Lichtenthaler HK. (1999). The 1-deoxy-D-xylulose-5-phosphate pathway of isoprenoid biosynthesis in plants. Annual Review of Plant Physiology and Plant Molecular Biology, 50, 47–65.
- Peer-reviewed Andre CM, Hausman J-F, Guerriero G. (2016). Cannabis sativa: The plant of the thousand and one molecules. Frontiers in Plant Science, 7, 19.
- Peer-reviewed Livingston SJ, Quilichini TD, Booth JK, et al. (2020). Cannabis glandular trichomes alter morphology and metabolite content during flower maturation. The Plant Journal, 101(1), 37–56.
- Peer-reviewed Ross SA, ElSohly MA. (1996). The volatile oil composition of fresh and air-dried buds of Cannabis sativa. Journal of Natural Products, 59(1), 49–51.
- Peer-reviewed Booth JK, Yuen MMS, Jancsik S, et al. (2020). Terpene synthases and terpene variation in Cannabis sativa. Plant Physiology, 184(1), 130–147.
- Peer-reviewed Smith CJ, Vergara D, Keegan B, Jikomes N. (2022). The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE, 17(5), e0267498.
- Peer-reviewed Russo EB. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- The Indica/Sativa Myth — The popular classification system contradicts genetics, chemistry, and controlled research...
- The Myrcene 0.5% Threshold — A viral cannabis rule with no peer-reviewed evidence behind it.
- Pinene — A volatile pine-scented monoterpene with documented lab activity but unproven cognitive ef...
- Sesquiterpenes — 15-carbon terpenes that give cannabis its woody, spicy, and earthy notes.
- Terpene Degradation During Drying — The chemical loss and transformation of cannabis volatiles from harvest to finished produc...
- Terpene Profiles Reliably Predict Effects — A popular claim that outpaced the evidence—and why it persists.
- Why Terpenes Matter (Or Don't) — Terpenes drive scent and flavor; effects claims are mostly preclinical or anecdotal.